Viatris stock
Price history
+93.25% over the period1 year: from $10.66 (November 17, 2025) to $20.60 (November 17, 2026), +93.25%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $20.60 |
| October 30, 2026 | $19.04 |
| September 30, 2026 | $17.72 |
| August 31, 2026 | $16.51 |
| July 31, 2026 | $17.56 |
| June 30, 2026 | $15.88 |
| May 29, 2026 | $16.26 |
| April 30, 2026 | $14.94 |
| March 31, 2026 | $13.51 |
| February 27, 2026 | $14.93 |
| January 30, 2026 | $13.09 |
| December 31, 2025 | $12.45 |
| November 28, 2025 | $10.69 |
| November 17, 2025 | $10.66 |
At a glance
The company
Produce and distribute prescription brand drugs, generic drugs, complex generics and biosimilars across multiple therapeutic areas globally
Latest results
Quarter to September 30, 2026 · EPS $0.71 (estimate $0.64)
Next event
Dividend
TickerLandia's take on Viatris
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.54% from the 52-week high
Analysts · 12 analysts
Average target$21.30+4.16% vs. price
Buy 7 · Hold 4 · Sell 1 · Buy
TickerLandia Fingerprint: Viatris
Compared with similar companies: very strong momentum and very low financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.
Earnings stabilitylow22
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.1% 36 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 9 Financial strengthvery low9
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 3.38 9 Interest coverage 2.62 9 Market momentumvery strong93
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +23.95% 83 1-year return +91.84% 97 Distance from 200-day average +25.35% 95 Relative strength (3 months) +31.58% 98 Risklow34
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.5% 28 Beta (1 year) 0.64 49 Maximum drawdown (12 months) 19.7% 25
4 dimensions without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
The financials
The business in numbers
Revenue
$3.75B
Latest quarter · Q3 2026
Net income
-$325.3M
Latest quarter · Q3 2026
Quarterly net margin
-8.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $23.58B
- Volume
- 745.8K
- Daily trading
- €163.31M
- Dividend yield
- 2.35%
How Viatris is changing
All resultsRevenue grew 3.7% a year on average over the last 5 years
Operating margin fell from 16.9% to 8.6%
Shares outstanding up 94.7% in 5 years
Returns
Viatris returns with dividends
$1,000 invested in Viatris 5 years ago, on November 17, 2021, would be worth $1,861 today with dividends reinvested: +86.14% in total, +13.23% per year. On price alone it would be $1,509 (+50.92%).
| Period | Viatris | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +12.81% | −3.17% | $1,128 |
| 6 months | +24.09% | +0.11% | $1,241 |
| Year to date | +65.46% | +8.34% | $1,655 |
| 1 year | +99.97% | +11.15% | $2,000 |
| 3 years | +147.07% | +64.30% | $2,471 |
| 5 years | +86.14% | +58.18% | $1,861 |
| 10 years | −31.36% | +239.10% | $686 |
Over the last 6 months it has done better than 61% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Viatris: technical analysis
Viatris is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 73.1% below its highest close since January 2, 1990 ($76.06, April 24, 2015).
- Trend
- Upward
- RSI (14 sessions)
- 64
- Between 30 and 70
- vs 200-session average
- +25.35%
Support and resistance
Price areas where Viatris has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$20.45
- Support$18.41−9.98%2 touches, last on September 29, 2026
- Support$17.97−12.15%2 touches, last on October 23, 2026
- Support$17.53−14.28%2 touches, last on May 14, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.64
- Volatility (60 sessions, annualised)
- 26.5%
- Largest fall in the last year
- −19.65%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Viatris: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Viatris has been November: +5.10% on average, positive in 24 years out of 36. The weakest has been April: −0.96% on average, positive in 14 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.32% | −0.67% | 17 of 36 |
| February | −0.24% | +0.21% | 19 of 37 |
| March | −0.57% | −0.14% | 18 of 37 |
| April | −0.96% | −3.10% | 14 of 37 |
| May | +1.66% | +0.52% | 20 of 37 |
| June | −0.87% | −0.41% | 17 of 37 |
| July | +0.01% | +1.07% | 21 of 37 |
| August | +1.83% | +0.65% | 20 of 37 |
| September | +0.52% | +0.28% | 19 of 37 |
| October | +1.37% | −0.09% | 18 of 37 |
| November | +5.10% | +4.02% | 24 of 36 |
| December | +3.19% | +3.84% | 23 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Viatris and its competitors
Viatris Inc. is based in Canonsburg, Pennsylvania, and has existed since its founding in 1961. Together with its subsidiaries, the healthcare company develops and sells prescription brand drugs, generic drugs, complex generics and biosimilars in areas such as cardiovascular, CNS and anesthesia, diabetes and metabolism, oncology, and respiratory and allergy. Its brands include Lipitor, Viagra, Lyrica and EpiPen Auto-Injector, supplied as oral solid doses, injectables and complex dosage forms to pharmacies, wholesalers, payers, insurers, governments and institutions.
- Headquarters
- Canonsburg, United States
- Employees
- 30,000
- Founded
- 1961
- Chief executive
- Scott Smith
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ViatrisVTRS | $23.58B | — | — | +24.09% |
| United TherapeuticsUTHR | $25.04B | 39.4% | 22.2 | +2.73% |
| Neurocrine BiosciencesNBIX | $16.73B | 26.6% | 24.5 | +4.73% |
| ZoetisZTS | $33.92B | 37.9% | 14.1 | +12.48% |
| Teva Pharmaceutical IndustriesTEVA | $49.67B | 19.8% | 99.0 | +24.29% |
| Hims & Hers HealthHIMS | $4.13B | -6.4% | — | −29.94% |
Same industry or related industries, similar size. Compare Viatris with its competitors · Full profile
